医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Macrogen Signs License and Supply Agreement with Thermo Fisher Scientific

2020年01月13日 PM11:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

Kap-Seok Yang, CEO of Macrogen (KOSDAQ: 038290), announced on January 13 that the company has signed a strategic License and Supply Agreement with Thermo Fisher Scientific. The agreement, which was recently signed, aims to expand the global market for Capillary Electrophoresis Sequencing (CES) service.

Macrogen is a precision medicine and biotechnology company. Please see www.macrogen.com. Thermo Fisher Scientific is a leading bioscience corporation employing more than 70,000 workers globally and earning upwards of USD 24 billion in annual revenues.

CES, a first-generation base sequence analysis method, accurately reads targeted pieces of genetic data. Recent developments in CES technology have increased the popularity of related applications and the growth rate of the CES market is accelerating. Global research firm Allied Market Research forecasts that the world CES market will grow to USD 185 million by 2025. Thermo Fisher Scientific is a leader in the global CES market.

Macrogen aims to improve its price competitiveness by using equipment and reagents from Thermo Fisher Scientific, which will provide customers in Korea and abroad with highly reliable, high-quality data.

Through the agreement, Macrogen plans to expand the overseas markets for CES services.

Macrogen’s strategy is to establish a ‘Genome Supermarket’ which provides consistently high-quality genetic analysis services to customers worldwide and improves customer access to services. As part of this effort, Macrogen has established laboratories in Spain and Singapore. Additional laboratories are also planned in Oceania and Europe.

Yang commented, “Macrogen is preparing to take the next big step in the market for CES, which has been key to the company’s initial growth and is growing rapidly thanks to the expansion of related applications.” He added, “Our agreement with global bio market leader Thermo Fisher Scientific will allow Macrogen to pursue global marketing that addresses the ongoing changes in the CES market.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20200113005027/en/

CONTACT

Macrogen Inc.

Hyun-Ah Lee, +82-2-2180-7029

pr@macrogen.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Imricor Announces First Sales Collaboration With Philips
  • Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
  • FDA Issues Emergency Use Authorization for Impella Heart Pumps to Provide Unloading Therapy to COVID-19 Patients
  • 患者安全运动基金会、美国麻醉师协会、Leapfrog集团和国际医疗保健品质协会共同举办#UniteForSafeCare世界患者安全日活动
  • 武田宣布2020财年第一季度业绩;确认管理层指引,并提高全年列报运营利润和列报净利润